News

May 9, 2012 — Sound Interventions Inc. announced the successful completion of the company's first-in-human clinical trial to treat resistant hypertension, SOUND-ITV.

May 4, 2012 - Medtronic Inc. announced six-month pooled outcomes from randomized and crossover patients in the Symplicity HTN-2 clinical trial following renal denervation with the Symplicity renal...

May 2, 2012 — Vessix Vascular Inc. announced this week that it has received CE mark approval for its V2 Renal Denervation System for the treatment of hypertension. Renal denervation is a...

April 24, 2012—Providing more guidance to clinicians on the provision of optimal patient care, the American College of Cardiology Foundation (ACCF), American Heart Association (AHA) and American...

April 19, 2012 — Spherix Inc. announced results from its recently completed studies using near-infrared spectroscopy on autopsy samples from humans who had confirmed cardiovascular disease....

ReCor Medical disclosed updated data for the REDUCE First-In-Man clinical study of its CE-marked Paradise (percutaneous renal denervation system) ultrasound platform, which is...

April 6, 2012 — The U.S. anticoagulant market is on the verge of a major shift in clinical practice, transitioning from a market dominated by a single injectable anticoagulant to a highly...

April 4, 2012 — Medtronic Inc. announced that the Symplicity renal denervation system provides safe, significant and sustained blood pressure reduction up to three years in patients with treatment...

It seems a picture is worth more than a thousand words for people who see evidence of coronary artery disease, the most common type of heart disease in men and women. Simply seeing a build-up of...

Internet-based telemedicine systems appear to lead to more appropriate and effective pharmacotherapy, better blood pressure control and an overall reduction in cardiovascular risk compared to...

March 29, 2012 — Adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the risk of recurrent cardiovascular events in a specific group of...

March 29, 2012 — A three-pronged intervention in Brazilian public hospitals significantly improved physician adherence to evidence-based protocols for treating acute coronary syndrome (ACS),...

March 27, 2012 – Researchers found the antiplatelet drug abciximab significantly decreased damage to the heart muscle in patients with ST-segment-elevation myocardial infarction (STEMI), the most...

March 19, 2012 – Individuals suffering from chronic heart failure (CHF) can look forward to the appearance of many new drug options over the next few years and place hope in a cure through future...

March 9, 2012 - Researchers say venom from the green mamba snake may aid in the preservation of cardiac and renal function following serious cardiovascular events, such as heart attack and acute...

March 8, 2012 — Transgenomic Inc. announced the publication of a new study by researchers at Vanderbilt University that further validates the role of both genes found in the company’s PGxPredict:...

March 7, 2012 — The U.S. Food and Drug Administration (FDA) notified healthcare professionals of updates to the prescribing information concerning interactions between protease...

February 29, 2012 — Vessix Vascular Inc. announced initial patient treatments in the international multi-center Reduce-HTN renal denervation clinical study for uncontrolled hypertension.

February 28, 2012 — Janssen Research and Development LLC announced that the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental new drug...

February 23, 2012 — AstraZeneca announced that the American College of Chest Physicians (ACCP) has updated its guidelines on Antithrombotic Therapy and Prevention of Thrombosis to include a...